# Ordspono™ (odronextamab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/odronextamab

> The PDUFA target action date for Ordspono™ (odronextamab), sponsored by REGENERON PHARMACEUTICALS, INC. (REGN), is Feb 2027. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Ordspono™ (odronextamab) |
| Codes | REGN1979, R1979 |
| Sponsor | REGENERON PHARMACEUTICALS, INC. (REGN) https://sec-api.dev/companies/regn/catalysts |
| Indications | relapsed/refractory fl and dlbcl due, [B-cell Non-Hodgkin Lymphoma (B-NHL)](https://sec-api.dev/indications/b-cell-non-hodgkin-lymphoma-b-nhl), [Follicular Lymphoma (FL)](https://sec-api.dev/indications/follicular-lymphoma-fl), [Diffuse Large B-cell Lymphoma (DLBCL)](https://sec-api.dev/indications/diffuse-large-b-cell-lymphoma-dlbcl) |
| Modality | antibody |
| FDA designations | none disclosed |

## Timeline

### March 22, 2024: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact. Stage: 3. Indication: relapsed/refractory FL and DLBCL due.
- First seen 2026-02-04, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761303Original1_20240322.pdf%22
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761303Original2_20240322.pdf%22
- SEC Form 10-Q (accession 0000872589-26-000034): "For example, in March 2024, the FDA issued CRLs concerning our BLA for odronextamab for the treatment of relapsed/refractory FL and DLBCL due to the enrollment status of confirmatory Phase 3 trials, which, along with the July 2025 CRL discussed below, has delayed the potential FDA approval of odronextamab." https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/regn-20260930.htm
- SEC Form 10-Q (accession 0000872589-26-000025): "For example, in March 2024, the FDA issued CRLs concerning our BLA for odronextamab for the treatment of relapsed/refractory FL and DLBCL due to the enrollment status of confirmatory Phase 3 trials, which, along with the July 2025 CRL discussed below, has delayed the potential FDA approval of odronextamab." https://www.sec.gov/Archives/edgar/data/872589/000087258926000025/regn-20260630.htm
- SEC Form 10-Q (accession 0000872589-26-000016): "For example, in March 2024, the FDA issued CRLs concerning our BLA for odronextamab for the treatment of relapsed/refractory FL and DLBCL due to the enrollment status of confirmatory Phase 3 trials, which, along with the July 2025 CRL discussed below, has delayed any potential FDA approval of odronextamab." https://www.sec.gov/Archives/edgar/data/872589/000087258926000016/regn-20260331.htm
- SEC Form 10-K (accession 0000872589-26-000008): "For example, in March 2024, the FDA issued CRLs concerning our BLA for odronextamab for the treatment of relapsed/refractory FL and DLBCL due to the enrollment status of confirmatory Phase 3 trials, which, along with the July 2025 CRL discussed below, has delayed any potential FDA approval of odronextamab." https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htm

### Jan 2025: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2025-02-04, last confirmed 2025-02-04.
- Press release filed with the SEC (EX-99) (accession 0001804220-25-000007): "•In January 2025, the Company resubmitted to the FDA the BLA for odronextamab, a bispecific antibody targeting CD20 and CD3, in R/R follicular lymphoma." https://www.sec.gov/Archives/edgar/data/872589/000180422025000007/exhibit991q42024.htm

### July 30, 2025: PDUFA date

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2025-02-04, last confirmed 2025-04-29.
- Press release filed with the SEC (EX-99) (accession 0001804220-25-000020): "•The FDA accepted for review the resubmission of the BLA for odronextamab, a bispecific antibody targeting CD20 and CD3, in relapsed/refractory (R/R) follicular lymphoma, with a target action date of July 30, 2025." https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/exhibit991q12025.htm
- Press release filed with the SEC (EX-99) (accession 0001804220-25-000007): "FDA decision on BLA for odronextamab (CD20 and CD3 bispecific antibody) in R/R follicular lymphoma (second half 2025)" https://www.sec.gov/Archives/edgar/data/872589/000180422025000007/exhibit991q42024.htm
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761303_20250730.pdf%22

### July 30, 2025: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2025-08-01, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761303_20250730.pdf%22
- Press release filed with the SEC (EX-99) (accession 0000872589-25-000017): "•On July 30, 2025, the FDA issued a Complete Response Letter (CRL) for the BLA for odronextamab, a bispecific antibody targeting CD20 and CD3, in relapsed/refractory follicular lymphoma after two or more lines of systemic therapy, which was also impacted by the Catalent Indiana LLC site inspection (as described above)." https://www.sec.gov/Archives/edgar/data/872589/000087258925000017/exhibit991q22025.htm

### June 17, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: B-cell Non-Hodgkin Lymphoma (B-NHL).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03888105 (A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-06-17 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT03888105

### Feb 2027: PDUFA date

- Status: scheduled. Date confidence: month.
- First seen 2026-10-30, last confirmed 2026-10-30.
- Press release filed with the SEC (EX-99) (accession 0000872589-26-000032): "•The FDA accepted for review the resubmission of the BLA for Ordspono™ (odronextamab) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), which has a target action date in February 2027." https://www.sec.gov/Archives/edgar/data/872589/000087258926000032/exhibit991q32026.htm

### Feb to May 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Follicular Lymphoma (FL).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06091254 (A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-29 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT06091254

### February 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Follicular Lymphoma (FL).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06091254 (A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-29 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT06091254

### Mar to Jun 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Diffuse Large B-cell Lymphoma (DLBCL).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06091865 (A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-30 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT06091865

### March 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Diffuse Large B-cell Lymphoma (DLBCL).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06091865 (A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-30 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT06091865

### May to Aug 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: B-Cell Non-Hodgkin Lymphoma (B-NHL).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06230224 (A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-05-29 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT06230224

### May 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: B-Cell Non-Hodgkin Lymphoma (B-NHL).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06230224 (A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-05-29 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT06230224

### Jul to Oct 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Follicular Lymphoma (FL).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06097364 (A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-07-29 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT06097364

### July 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Follicular Lymphoma (FL).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06097364 (A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-07-29 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT06097364

## Same indication

- [TEPKINLY (epcoritamab)](https://sec-api.dev/pdufa/epcoritamab) (GMAB)
- [Tisagenlecleucel](https://sec-api.dev/pdufa/tisagenlecleucel) (NVS)

Calendar months: [February 2028](https://sec-api.dev/fda-calendar/2028-02), [March 2028](https://sec-api.dev/fda-calendar/2028-03), [May 2028](https://sec-api.dev/fda-calendar/2028-05)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/odronextamab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Ordspono™ (odronextamab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/odronextamab

```bibtex
@misc{secapidev_pdufa_odronextamab_20261116,
  title        = {Ordspono™ (odronextamab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/odronextamab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_odronextamab_20261116","title":"Ordspono™ (odronextamab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/odronextamab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
